Sunesis publish information on discovery of Aurora kinase inhibitor

Sunesis have published  data on an Aurora kinase inhibitor

PI3K inhibitor administration improves Doxorubicin activity in breast cancer cells

Preclinical data shows that administration of PI3K inhibitor LY294002 enhances the anticancer activity of doxorubicin on breast cancer cells in vitro

Pharmacopeia receive milestone from Wyeth in JAK3 collaboration

Pharmacopeia have received a milestone payment from Wyeth Pharmaceuticals for identifying a systemically administered JAK3 kinase inhibitor for the treatment of immunological and inflammatory diseases.

Cytopia gearing up for JAK2 clinical trial

Cytopia have appointed a Study chair at the Mayo Clinic in preparation of Phase I JAK2 trials for myelofibrosis